Wall Street analysts expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to post ($0.10) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Aevi Genomic Medicine’s earnings. Aevi Genomic Medicine posted earnings of ($0.14) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The firm is scheduled to issue its next earnings report on Thursday, August 15th.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.27) per share for the current fiscal year. For the next financial year, analysts expect that the firm will post earnings of ($0.18) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03.
GNMX stock remained flat at $$0.19 during midday trading on Friday. The company had a trading volume of 455,617 shares, compared to its average volume of 3,719,725. The stock has a market capitalization of $11.96 million, a PE ratio of -0.38 and a beta of 0.73. The stock has a fifty day moving average price of $0.18. Aevi Genomic Medicine has a fifty-two week low of $0.15 and a fifty-two week high of $1.40.
A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Vanguard Group Inc. lifted its position in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 82.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,252,050 shares of the biotechnology company’s stock after purchasing an additional 566,497 shares during the period. Vanguard Group Inc. owned about 1.93% of Aevi Genomic Medicine worth $201,000 as of its most recent filing with the Securities and Exchange Commission. 6.45% of the stock is currently owned by institutional investors.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: Stock Symbols Definition, Examples, Lookup
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.